Latest Bladder Cancer News
An interview with David J. McConkey, PhD
Based on a small study, investigators report encouraging efficacy and safety.
Increased type I collagen mRNA expression in the extracellular matrix microenvironment is associated with poor progression-free survival.
Patients who underwent a radical cystectomy (RC) developed postoperative infection after a median of 13 days.
Patients with diabetes had a significant 42% increased risk of recurrence of cancer and 79% increased risk of progression.
This approach is associated with a 26% decreased risk of disease recurrence at 15 years compared with alternating therapy with mitomycin C.
Tumors in the dome or urachus confer a better prognosis than those in the lateral wall and base, study finds.
Assay could cut down on cystoscopies, researchers say.
Second cancer was fatal in 55% of the cases studied.
Diabetics taking the drug had a significant 68% decreased risk of grade progression compared with diabetics not on the drug.
Researchers find no difference in 5-year disease-specific survival between multi-disciplinary bladder-sparing approach and radical cystectomy.
During first 24 months, 8.7% of patients with favorable pathological characteristics had progressed.
Women with stage IV bladder cancer have a lower median overall survival rate when compared to men.
About a quarter of older patients deemed too frail for chemo responded to atezolizumab.
Four key lifestyle factors include weight, exercise, no smoking, and limiting alcohol.
Atezolizumab received accelerated FDA approval for patients whose disease has progressed despite platinum-based chemotherapy.
Bladder Cancer Videos
Renal and Urology News Articles
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)